ADAM9 and cancer: Hence, use of an ADAM9 inhibitor for PCa treatment might exert unpredictable toxicities, just like other MMP inhibitors which were reported to induce intolerable musculoskeletal pain and inflammation in cancer treatment clinical trials36.